Scorpius Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Scorpius Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $5.79M | Apr 24, 2019 |
| FY2018 | Dec 31, 2017 | $1.52M | Apr 24, 2019 |
| FY2017 | Dec 31, 2016 | $341.6K | Mar 2, 2018 |
| FY2013 | Dec 31, 2013 | $585.6K | Oct 10, 2014 |
| FY2013 | Dec 31, 2012 | $3.1K | Oct 10, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($32.81M) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | ($45.22M) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | ($43.43M) | Apr 26, 2024 |
| FY2022 | Sep 30, 2022 | ($13.26M) | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | ($6.83M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($35.07M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($26.05M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($20.02M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($15.73M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($11.84M) | Apr 24, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($33.60M) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | ($42.03M) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | ($40.22M) | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | ($35.42M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($26.12M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($20.75M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($17.96M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($13.34M) | Apr 24, 2019 |
| FY2017 | Dec 31, 2016 | ($13.13M) | Mar 2, 2018 |
| FY2016 | Dec 31, 2015 | ($21.02M) | Mar 31, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $14.33M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $20.12M | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | $20.22M | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | $16.46M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $12.94M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $13.01M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $16.23M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $8.27M | Apr 24, 2019 |
| FY2017 | Dec 31, 2016 | $9.33M | Mar 2, 2018 |
| FY2016 | Dec 31, 2015 | $16.67M | Mar 31, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $21.57M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $26.17M | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | $20.13M | Apr 26, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($26.01M) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | ($31.53M) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | ($5.70M) | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | ($38.13M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($22.02M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($12.84M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($21.71M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($6.40M) | Apr 24, 2019 |
| FY2017 | Dec 31, 2016 | ($13.52M) | Mar 2, 2018 |
| FY2014 | Dec 31, 2014 | ($9.83M) | Mar 27, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $875.2K | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $1.99M | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | $20.12M | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.90M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $338.0K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $265.2K | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $593.6K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $61.4K | Apr 24, 2019 |
| FY2017 | Dec 31, 2016 | $45.9K | Mar 2, 2018 |
| FY2016 | Dec 31, 2015 | $115.5K | Mar 31, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $39.18M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $51.04M | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | $104.40M | Apr 26, 2024 |
| FY2022 | Sep 30, 2022 | $119.91M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $120.96M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $124.19M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $25.96M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $37.76M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $20.19M | Apr 24, 2019 |
| FY2017 | Dec 31, 2016 | $8.90M | Mar 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $37.50M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $22.74M | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | $31.96M | Apr 26, 2024 |
| FY2022 | Sep 30, 2022 | $33.71M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $33.14M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $8.93M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $8.70M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $12.80M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $7.52M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $14.41M | Apr 24, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.30M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $31.40M | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | $73.92M | Apr 26, 2024 |
| FY2022 | Sep 30, 2022 | $87.54M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $99.96M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $113.11M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $116.24M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $13.57M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $30.29M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $7.37M | Apr 24, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.30M | Mar 31, 2023 |
| FY2022 | Sep 30, 2022 | $3.21M | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | $1.45M | Mar 31, 2023 |
| FY2020 | Dec 31, 2019 | $1.45M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.19M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.19M | Apr 24, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($287.18M) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | ($254.37M) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | ($209.15M) | Apr 26, 2024 |
| FY2022 | Sep 30, 2022 | $193.93M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $180.67M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($165.72M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($130.65M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($104.60M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($84.58M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($68.85M) | Apr 24, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.03M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | $184.9K | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | $3.19M | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | $8.05M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $10.93M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $9.04M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $22.15M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $9.76M | Apr 24, 2019 |
| FY2017 | Dec 31, 2016 | $7.84M | Mar 2, 2018 |
| FY2017 | Dec 31, 2015 | $4.94M | Mar 2, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2014 | $6.94M | Feb 18, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (13) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | (347) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 26, 2024 |
| FY2022 | Sep 30, 2022 | 0 | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 11, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (13) | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | (347) | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 26, 2024 |
| FY2022 | Sep 30, 2022 | 0 | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 11, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 5.08M | Apr 30, 2025 |
| FY2024 | Dec 31, 2023 | 130,979 | Apr 30, 2025 |
| FY2023 | Dec 31, 2022 | 25.66M | Apr 26, 2024 |
| FY2022 | Dec 31, 2021 | 25.65M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 22.83M | Mar 11, 2022 |
| FY2021 | Dec 11, 2020 | 22.80M | Mar 11, 2022 |
| FY2021 | Dec 10, 2020 | 159.80M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 4.83M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 32.49M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 4.20M | Apr 24, 2019 |